PhD, University of Minnesota, 1969.
Post-Doctoral Fellowship, University of Minnesota, 1971.
Department of Health Policy and Management
(410) 550-0035, (410) 550-0036
Honors and Awards
- USPHS Research Scientist Development Award and Research Scientist Award: 1977-2003.
- Fellow of College on Problems of Drug Dependence
- Fellow of American Psychological Association
- Fellow of American Psychological Society
- Fellow of Society of Behavioral Medicine.
- President of Division of Psychopharmacology of the American Psychological Association, 1987-1988
- President of College on Problems of Drug Dependence, 1993-94.
- Nyswander/Dole (Marie) Award, American Methadone Treatment Assoc, 1997.
Dr. Bigelow serves as the Director of the Behavioral Pharmacology Research Unit (BPRU), a multi-faceted clinical research program dealing with the interaction between environmental/behavioral factors and pharmacological factors, and specializing in studies of substance abuse and its treatment. He directs the Unit’s postdoctoral research training program and has overall responsibility for planning, oversight and supervision of the major elements of BPRU’s research resources -- a recruitment and assessment screening program for enrolling volunteers with appropriate substance use/abuse histories; operation of a 14-bed residential research facility; operation of a 175-slot outpatient substance abuse treatment research clinic; traininng and supervision of research fellows and research staff in conduct of behavioral medicine-related and substance abuse-related clinical research. Recent funded projects are listed and described below. In addition to the above-mentioned resource-management responsibilities Dr. Bigelow’s role includes participation in:
• study conceptualization and design;
• selection and planning of study interventions and/or independent-variable manipulations;
• selection and planning of the dependent-variable outcome assessments, including subjective, behavioral, and physiological indices;
• consideration and planning of human subjects issues, including appropriate recruitment, care, and aftercare provision;
• review, analysis, and interpretation of data;
• manuscript preparation.
Correia CJ, Walsh SL, Bigelow GE, Strain EC. Effects associated with double-blind omission of buprenorphine/naloxone over a 98-h period. Psychopharmacology (Berl). 2006 Dec;189(3):297-306. Epub 2006 Sep 30.
Carroll CP, Walsh SL, Bigelow GE, Strain EC, Preston KL. Assessment of agonist and antagonist effects of tramadol in opioid-dependent humans. Exp Clin Psychopharmacol. 2006 May;14(2):109-20.
Donny EC, Bigelow GE, Walsh SL. Comparing the physiological and subjective effects of self-administered vs yoked cocaine in humans. Psychopharmacology (Berl). 2006 Jul;186(4):544-52. Epub 2006 Mar 21.
Sigmon SC, Moody DE, Nuwayser ES, Bigelow GE. An injection depot formulation of buprenorphine: extended bio-delivery and effects. Addiction. 2006 Mar;101(3):420-32.
Marsch LA, Stephens MA, Mudric T, Strain EC, Bigelow GE, Johnson RE. Predictors of outcome in LAAM, buprenorphine, and methadone treatment for opioid dependence. Exp Clin Psychopharmacol. 2005 Nov;13(4):293-302.
Donny EC, Brasser SM, Bigelow GE, Stitzer ML, Walsh SL. Methadone doses of 100 mg or greater are more effective than lower doses at suppressing heroin self-administration in opioid-dependent volunteers. Addiction. 2005 Oct;100(10):1496-509.
Lofwall MR, Brooner RK, Bigelow GE, Kindbom K, Strain EC. Characteristics of older opioid maintenance patients. J Subst Abuse Treat. 2005 Apr;28(3):265-72.
Jones HE, Johnson RE, Bigelow GE, Silverman K, Mudric T, Strain EC. Safety and efficacy of L-tryptophan and behavioral incentives for treatment of cocaine dependence: a randomized clinical trial. Am J Addict. 2004 Oct-Dec;13(5):421-37.
Brooner RK, Kidorf MS, King VL, Stoller KB, Peirce JM, Bigelow GE, Kolodner K. Behavioral contingencies improve counseling attendance in an adaptive treatment model. J Subst Abuse Treat. 2004 Oct;27(3):223-32.
Sigmon SC, Wong CJ, Chausmer AL, Liebson IA, Bigelow GE. Evaluation of an injection depot formulation of buprenorphine: placebo comparison. Addiction. 2004 Nov;99(11):1439-49.
Silverman K, Robles E, Mudric T, Bigelow GE, Stitzer ML. A randomized trial of long-term reinforcement of cocaine abstinence in methadone-maintained patients who inject drugs. J Consult Clin Psychol. 2004 Oct;72(5):839-54.
Hendrix CW, Wakeford J, Wire MB, Lou Y, Bigelow GE, Martinez E, Christopher J, Fuchs EJ, Snidow JW. Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with amprenavir in opioid-dependent subjects. Pharmacotherapy. 2004 Sep;24(9):1110-21.
Strain EC, Moody DE, Stoller KB, Walsh SL, Bigelow GE. Relative bioavailability of different buprenorphine formulations under chronic dosing conditions. Drug Alcohol Depend. 2004 Apr 9;74(1):37-43.
Sobel BF, Sigmon SC, Walsh SL, Johnson RE, Liebson IA, Nuwayser ES, Kerrigan JH, Bigelow GE. Open-label trial of an injection depot formulation of buprenorphine in opioid detoxification. Drug Alcohol Depend. 2004 Jan 7;73(1):11-22.
Donny EC, Bigelow GE, Walsh SL. Assessing the initiation of cocaine self-administration in humans during abstinence: effects of dose, alternative reinforcement, and priming. Psychopharmacology (Berl). 2004 Mar;172(3):316-23. Epub 2003 Nov 28.
Houtsmuller EJ, Notes LD, Newton T, van Sluis N, Chiang N, Elkashef A, Bigelow GE. Transdermal selegiline and intravenous cocaine: safety and interactions. Psychopharmacology (Berl). 2004 Feb;172(1):31-40. Epub 2003 Nov 6.
Griffiths RR, Bigelow GE, Ator NA. Principles of initial experimental drug abuse liability assessment in humans. Drug Alcohol Depend. 2003 Jun 5;70(3 Suppl):S41-54. Review.
Balster RL, Bigelow GE. Guidelines and methodological reviews concerning drug abuse liability assessment. Drug Alcohol Depend. 2003 Jun 5;70(3 Suppl):S13-40. Review.
Walsh SL, Strain EC, Bigelow GE. Evaluation of the effects of lofexidine and clonidine on naloxone-precipitated withdrawal in opioid-dependent humans. Addiction. 2003 Apr;98(4):427-39.
Donny EC, Bigelow GE, Walsh SL. Choosing to take cocaine in the human laboratory: effects of cocaine dose, inter-choice interval, and magnitude of alternative reinforcement. Drug Alcohol Depend. 2003 Apr 1;69(3):289-301.
Zacny J, Bigelow GE, Compton P, Foley K, Iguchi M, Sannerud C. College on Problems of Drug Dependence taskforce on prescription opioid non-medical use and abuse: position statement. Drug Alcohol Depend. 2003 1;69(3):215-32.
Balster RL, Bigelow GE. Guidelines and methodological reviews concerning drug abuse liability assessment. Drug Alcohol Depend. 2003 5;70(3 Suppl):S13-40.
Bigelow GE, Rand, C.S. (2003 ). Tobacco use and dependence. In LR Barker, JR Burton, PD Zieve (Eds.) Principles of Ambulatory Medicine, Sixth Edition, Lippincott Williams & Wilkins, Philadelphia, PA, pp 321-333.
Silverman K, Svikis D, Wong CJ, Hampton J, Stitzer ML, Bigelow GE. A reinforcement-based therapeutic workplace for the treatment of drug abuse: three-year abstinence outcomes. Exp Clin Psychopharmacol. 2002;10(3):228-40.
Strain EC, Walsh SL, Bigelow GE. Blockade of hydromorphone effects by buprenorphine/naloxone and buprenorphine. Psychopharmacology (Berl). 2002;159(2):161-6.
Strain EC, Walsh SL, Bigelow GE. Blockade of hydromorphone effects by buprenorphine/naloxone and buprenorphine. Psychopharmacology (Berl). 2002 Jan;159(2):161-6. Epub 2001 Oct 12.
Silverman K, Svikis D, Wong CJ, Hampton J, Stitzer ML, Bigelow GE. A reinforcement-based therapeutic workplace for the treatment of drug abuse: three-year abstinence outcomes. Exp Clin Psychopharmacol. 2002 Aug;10(3):228-40.
Robles E, Stitzer ML, Strain EC, Bigelow GE, Silverman K. Voucher-based reinforcement of opiate abstinence during methadone detoxification. Drug Alcohol Depend. 2002 Jan 1;65(2):179-89.